Risk of Stroke after Herpes Zoster - Evidence from a German Self-Controlled Case-Series Study
- PMID: 27880853
- PMCID: PMC5120818
- DOI: 10.1371/journal.pone.0166554
Risk of Stroke after Herpes Zoster - Evidence from a German Self-Controlled Case-Series Study
Abstract
Background: Herpes zoster (HZ) is caused by reactivation of the latent varicella-zoster virus (VZV). A severe complication of HZ is VZV vasculopathy which can result in ischemic or hemorrhagic stroke. The aims of our study were to assess the risk of stroke after the onset of HZ and to investigate the roles of stroke subtype, HZ location and the time interval between HZ onset and stroke.
Methods: A self-controlled case-series study was performed on a cohort of patients with incident stroke recorded in the German Pharmacoepidemiological Research Database (GePaRD), which covers about 20 million persons throughout Germany. We estimated adjusted incidence rate ratios (IRR) by comparing the rate of stroke in risk periods (i.e., periods following HZ) with the rate of stroke in control periods (i.e., periods without HZ) in the same individuals, controlling for both time-invariant and major potentially time-variant confounders.
Results: The cohort included 124,462 stroke patients, of whom 6,035 (5%) had at least one HZ diagnosis identified in GePaRD either as main hospital discharge diagnosis or as HZ treated with antivirals. The risk of stroke was about 1.3 times higher in the risk periods 3 months after HZ onset, than in the control periods (IRR: 1.29; 95% confidence interval: 1.16-1.44). An elevated risk of similar magnitude was observed for ischemic and unspecified stroke, but a 1.5-fold higher risk was observed for hemorrhagic stroke. A slightly stronger effect on the risk of stroke was also observed during the 3 months after HZ ophthalmicus (HZO) onset (1.59; 1.10-2.32). The risk was highest 3 and 4 weeks after HZ onset and decreased thereafter.
Conclusions: Our study corroborates an increased risk of stroke after HZ, which is highest 3 to 4 weeks after HZ onset. The results suggest that the risk is more pronounced after HZO and is numerically higher for hemorrhagic than for ischemic stroke.
Conflict of interest statement
HB is a full time employee of Sanofi Pasteur MSD. This study was funded by Sanofi Pasteur. TS, SB, KT, and EG as employees of the Leibniz Institute for Prevention Research and Epidemiology – BIPS have performed research studies paid by pharmaceutical companies (Bayer-Schering, Celgene, GSK, Mundipharma, Novartis, Purdue, Sanofi-Aventis, Sanofi- Pasteur, Stada, and Takeda) unrelated to this study. EG has been a consultant to Bayer, Novartis, Nycomed, Takeda, GSK, Astellas on topics unrelated to the subject of this study. SB left BIPS and joined Novartis Pharma AG after conduct of the study. Except for finalization of the manuscript, the entire analysis and results interpretation was performed under BIPS affiliation. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.
Figures


References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical